Skip to main content

Vivo Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$17.4B
Total invested
$132.0M
Avg. check
22
Industries
Biotechnology 21Health Care 14Therapeutics 11Pharmaceutical 10Biopharma 8Life Science 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 165
Atekka
September 2022

Atekka is a new generation agricultural insurance company.

Agriculture · Paris$4.9M Venture - Series Unknown
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post-IPO Equity
Semnur Pharmaceuticals
September 2025

Semnur Pharmaceuticals is a specialty pharmaceutical company focusing on clinical and commercial development of innovative products.

Biotechnology · Los Altos$100.0M Post-IPO Equity
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post-IPO Equity
Allakos
September 2022

Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.

Biopharma · Redwood City$150.0M Post-IPO Equity
Serán Bioscience
September 2024

Serán Bioscience is a contract development and manufacturing organization.

Biotechnology · Bend$200.0M Private Equity
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$25.0M Post-IPO Equity
Neurogastrx
August 2021

A private biopharmaceutical company .

Biotechnology · Woburn$60.0M Series B
Compass Therapeutics
August 2025

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Biopharma · Boston$120.0M Post-IPO Equity
Ocelot Bio
July 2023

Ocelot Bio brings new treatment options to patients with severe liver disease.

Biotechnology · San Diego$3.0M Debt Financing
Inspirna
July 2022

Inspirna is a biotechnology company developing drugs for the treatment of cancer.

Biotechnology · New York$55.1M Series D
INBRACE
July 2022

Swift Health Systems is a stealth stage start-up medical device company, developing INBRACE.

Consumer · Irvine$45.0M Debt Financing
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post-IPO Equity
Celcuity
June 2026

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Biotechnology · Hamel$500.0M Post-IPO Debt
Cerebral Therapeutics
June 2022

Cerebral Therapeutics is a clinical-stage pharmaceutical company.

Biotechnology · Aurora$40.0M Series C
ALX Oncology
June 2026

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Biopharma · San Francisco$10.0M Post-IPO Debt
OneChain Immunotherapeutics
June 2023

OCI develops therapies for leukaemia based on CAR–T.

Biotechnology · Barcelona$7.3M Seed
IGM Biosciences
June 2023

IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.

Biotechnology · Mountain View$107.3M Post-IPO Equity
Legend Biotech
June 2026

Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.

Biotechnology · Piscataway$226.0M Post-IPO Equity
Mereo Biopharma
June 2024

Mereo is a new UK-based speciality biopharmaceutical company.

Biopharma · London$50.0M Post-IPO Equity
SonoThera
June 2026

SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.

Biopharma · South San Francisco$125.0M Series B
Signadori Bio
May 2026

Signadori Bio is the next-generation cellular immunotherapy for cancer cure.

Manufacturing · Paris$13.0M Seed
Clene Nanomedicine
May 2026

Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.

Biotechnology · Salt Lake City$7.0M Post-IPO Equity

Where Vivo Capital invests

Biotechnology21
Health Care14
Therapeutics11
Pharmaceutical10
Biopharma8
Life Science6

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Biopharma. The firm invests across 22 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Celcuity received $500.0M in a Post-IPO Debt round. Vivo Capital's total known invested capital is $17.4B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $132.0M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include Atekka, IO Biotech, Semnur Pharmaceuticals, Ventyx Biosciences, Allakos. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →